Pancreatic Cancer|omicsgroup|journal Of Integrative Oncology

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Pancreatic Cancer Articles

The articles related to rice nutrition are published in journals of OMICS International, which are of high impact factor .These articles are of high quality standards and have numerous citations .These articles is peer reviewed by eminent editorial members . OMICS Group international is an Open Access publisher that publishes about 700+ peer-reviewed journals on a variety of subjects with the team of above 25000 editorial board members. It organizes over 3000+ International Scientific Conferences. The quality manuscripts related to rice nutrition is available in OMICS journal of Rice research open access. The group presented outcomes in patients with pancreatic adenocarcinoma associated with BRCA2 mutations with a focus on benefits of chemotherapeutic agents targeting the DNA repair deficits in BRCA2 mutation. Patients with a known BRCA mutation and pancreatic adenocarcinoma were identified in a retrospective chart review. Ten patients were identified of which 4 (40%) were of Ashkenazi heritage and 4 (40%) had a personal history of malignancy. Seven patients (70%) received platinum-based therapy, two (20%) received mitomycin-C, one (10%) received PARP inhibitor, and seven (70%) received a topoisomerase-I inhibitor. One patient receiving gemcitabine and irinotecan demonstrated a complete response after 6 months of therapy. She received an 8-month course before recurrence 4 months afterwards. Another patient received irinotecan as second-line therapy for 81 weeks. Cetuximab was added to irinotecan with stable disease for 52 weeks (for a combined duration of 133 weeks). Overall, clinical and radiologic responses were seen with various cytotoxic agents all targeting DNA repair deficiencies in BRCA2 mutation. These data highlights that BRCA2 patients may have a unique biology underlying their malignancies and that genetic testing may guide therapeutic choices in the future. Citation: Vyas OH, Leung K, Saif MW. Clinical Outcomes in Pancreatic Adenocarcinoma Associated with BRCA2 Mutation. Paper presented at the 48th Annual Meeting of the Pancreas Club; May 2014; Chicago, Illinois, USA.
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on June, 2021